Tenaya Therapeutics, Inc.
TNYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8 | $9 | $9 | $4 |
| Gross Profit | -$8 | -$9 | -$9 | -$4 |
| % Margin | – | – | – | – |
| R&D Expenses | $87 | $98 | $95 | $54 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $21 | $24 | $22 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $107 | $123 | $117 | $69 |
| Operating Income | -$116 | -$131 | -$126 | -$73 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $7 | $2 | $0 |
| Pre-Tax Income | -$111 | -$124 | -$124 | -$73 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$111 | -$124 | -$124 | -$73 |
| % Margin | – | – | – | – |
| EPS | -1.31 | -1.68 | -2.76 | -1.69 |
| % Growth | 22% | 39.1% | -63.3% | – |
| EPS Diluted | -1.31 | -1.68 | -2.76 | -1.69 |
| Weighted Avg Shares Out | 85 | 74 | 45 | 41 |
| Weighted Avg Shares Out Dil | 85 | 74 | 45 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $7 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $9 | $9 | $4 |
| EBITDA | -$103 | -$115 | -$115 | -$69 |
| % Margin | – | – | – | – |